Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Profit After Tax: 2012-2025

Historic Profit After Tax for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Profit After Tax fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$401.3 million, marking a year-over-year decrease of 159.51%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Profit After Tax stood at -$103.4 million, which was up 7.67% from -$112.0 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Profit After Tax's 5-year high stood at $1.9 billion during Q1 2021, with a 5-year trough of -$112.0 million in Q2 2025.
  • Its 3-year average for Profit After Tax is $1.5 million, with a median of -$91.3 million in 2023.
  • In the last 5 years, Agios Pharmaceuticals' Profit After Tax skyrocketed by 4,756.01% in 2021 and then crashed by 362.66% in 2023.
  • Agios Pharmaceuticals' Profit After Tax (Quarterly) stood at -$94.6 million in 2021, then skyrocketed by 138.60% to $36.5 million in 2022, then crashed by 362.66% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then slumped by 110.91% to -$103.4 million in 2025.
  • Its last three reported values are -$103.4 million in Q3 2025, -$112.0 million for Q2 2025, and -$89.3 million during Q1 2025.